929087-94-5

Basic information

• Product Name: 3-[2-(2-{2-[2-(2-{2-[2-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenylcarbamoyl)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-propionic acid
• Synonyms: 3-[2-(2-{2-[2-(2-{2-[2-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenylcarbamoyl)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-propionic acid
• CAS NO: 929087-94-5
• Molecular Weight: 701.809
• Mol File: 929087-94-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-[2-(2-{2-[2-(2-{2-[2-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenylcarbamoyl)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[2-(2-{2-[2-(2-{2-[2-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenylcarbamoyl)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-propionic acid(929087-94-5)
• EPA Substance Registry System: 3-[2-(2-{2-[2-(2-{2-[2-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenylcarbamoyl)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-propionic acid(929087-94-5)

Safety Data

• Hazardous Substances Data: 929087-94-5(Hazardous Substances Data)

Upstream product

• 782475-32-5 4-{2-[2-(2-Methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenylamine 
• 94376-75-7 3-(2-{2-[2-(2-{2-[2-(2-Carboxyethoxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy}-ethoxy)propionic acid 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 123-54-6 acetylacetone 
• 782475-33-6 C₁₆H₂₁NO₆ 
• 192650-25-2 6-(4-nitrophenyl)hexane-2,4-dione 

Relevant articles and documents

Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodies

Aryl sulfonamide-based endothelin antagonists were synthesized and covalently linked to the reactive lysine of the m38C2 antibody to create a series of CovX-Bodies. These chemically programmed antibodies behaved as potent endothelin receptor antagonists in vitro and had antitumor efficacy in a prostate cancer xenograft model which, on a molar basis, far exceeded the activity of the parent small molecule.